PracticeUpdate Dermatology February 2019

With Cosentyx:

4 out of 10 patients achieved PASI 100* 1

7 out of 10 patients achieved PASI 90* 1 9 out of 10 responders maintained their PASI response for up to 5 years * 1,2

*PASI 75/90/100 responses at Year 1 (88.9%, 68.5% and 43.8%, respectively) were sustained to Year 5 (88.5%, 66.4% and 41%) 1

See Product Information before prescribing. Refer to the primary advertisement in this publication for PBS and Product Information details.

Abbreviations: PASI: Psoriasis Area and Severity Index. References: 1. Bissonnette R et al. J Eur Acad Dermatol Venereol 2018 Feb 14. doi: 10.1111/jdv.14878. 2. Bissonnette R, et al. Br J Dermatol 2017; 177:1033–42. Cosentyx is a registered trade mark of Novartis AG. Novartis Pharmaceuticals Australia Pty Limited. ABN 18 004 244 160. 54 Waterloo Road, Macquarie Park NSW 2113. Ph (02) 9805 3555. AU-6737. August 2018. NODE14051W/PUCc. Ward6